

18 March 2018

April 2019 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **April 2019** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Atazanavir sulphate (Teva) cap 150 mg (p'code 2560461) and 200 mg (p'code 2563118) – Special Authority – Retail pharmacy
- Efavirenz with emtricitabine and tenofovir disoproxil (Mylan) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – Special Authority – Retail pharmacy (p'code 2558505)
- Emtricitabine with tenofovir disoproxil (Teva) tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – subsidy by endorsement; can be waived by Special Authority (p'code 2560488)
- Flutamide (Flutamide Mylan) tab 250 mg – Retail pharmacy-Specialist, S29 and wastage claimable (p'code 2564262)
- Gentamicin sulphate (Pfizer) inj 40 mg per ml, 2 ml ampoule, 50 inj pack – subsidy by endorsement (p'code 2498588)
- Influenza vaccine (Influvac Tetra) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – only on a prescription and no patient co-payment payable (Pharmacode change) (p'code 2558483)
- Morphine hydrochloride (Ordine) oral liq 5 mg per ml, 200 ml (p'code 2564378) and 10 mg per ml, 200 ml (p'code 2564386) – only on a controlled drug form, no patient co-payment payable, safety medicine, S29 and wastage payable
- Tetracosactrin (Synacthen S29) inj 250 mcg per ml, 1 ml ampoule – S29 and wastage claimable (p'code 2564300)

Changes to restrictions, chemical names and presentations

- Clarithromycin (Apo-Clarithromycin) tab 250 mg – amended restriction
- Efavirenz with emtricitabine and tenofovir disoproxil tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) (Atripla) and tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) (Mylan) – amended chemical and presentation name and note
- Emtricitabine with tenofovir disoproxil tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate) (Truvada) and tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) (Teva) – amended chemical and presentation name, endorsement and note
- Entecavir (Entecavir Sandoz) tab 0.5 mg – Brand switch fee removed

- Influenza vaccine inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) (Fluarix Tetra) and inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) (Influvac Tetra) – amended criteria

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Epirubicin hydrochloride	Inj 1 mg for ECP	Baxter
Irinotecan hydrochloride	Inj 1 mg for ECP	Baxter
Hydrocortisone butyrate	Lipocream 0.1%, 30 g OP	Locoid Lipocream
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml ampoule	Pfizer
Phenelzine sulphate	Tab 15 mg	Nardil

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Baclofen	Inj 2 mg per ml, 5 ml ampoule	Medsurge*	Lioresal Intrathecal
Carboplatin	Inj 10 mg per ml, 45 ml vial	Carboplatin Ebewe DBL Carboplatin* Carbaccord*	
Glycerin with sodium saccharin	Suspension	Ora-Sweet SF	
Glycerin with sucrose	Suspension	Ora-Sweet	
Lidocaine [lignocaine] hydrochloride	Inj 1%, 20 ml vial Inj 2%, 20 ml vial	Lidocaine-Clarix	
Mercaptopurine	Tab 50 mg	Puri-nethol	
Methylcellulose	Suspension	Ora-Sweet	
Methylcellulose with glycerin and sodium saccharin	Suspension	Ora-Blend SF	
Methylcellulose with glycerin and sucrose	Suspension	Ora-Blend	
Moclobemide	Tab 150 mg & 300 mg	Aurorix*	Apo-Moclobemide

* no subsidy changes for these brands for 1 April 2019.